Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia

Movement Disorders

Volumn 25, Issue 13, 2010, Pages 2188-2194

  Zhornitsky, Simon ^a   Stip, Emmanuel ^a   Pampoulova, Tania ^a,b   Rizkallah, Élie ^a,b   Lipp, Olivier ^a   Bentaleb, Lahcen Aït ^a   Chiasson, Jean Pierre ^b   Potvin, Stéphane ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b Clinique du Nouveau Depart   (Canada)

Author keywords

Antipsychotics; Extrapyramidal symptoms; Schizophrenia; Substance use disorders

Indexed keywords

ALCOHOL; AMPHETAMINE; CANNABIS; CLOZAPINE; COCAINE; FLUPENTIXOL; HALOPERIDOL; OLANZAPINE; PHENCYCLIDINE; PSYCHEDELIC AGENT; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; COCAINE DEPENDENCE; DETOXIFICATION; DISEASE EXACERBATION; DRUG DEPENDENCE; DRUG SCREENING; DRUG URINE LEVEL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 78649249136     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23227     Document Type: Article

References (59)

1. Eaton WW, Martins SS, Nestadt G, Bienvenu OJ, Clarke D, Alexandre P. The burden of mental disorders. Epidemiol Rev 2008;30:1-14.
2. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008;161:235-247.
3. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 2007;68 (Suppl 14):14-19.
4. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70 (Suppl 4):1-46; quiz47-48.
5. Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez de Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry 2001;1:7.
6. Offermans S, Rosenthal W. Encyclopedia of molecular pharmacology, 2nd ed. Berlin: Springer-Verlag; 2008.
7. Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 2002;14:123-129.
8. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57:PL103-PL107.
9. Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 2002;162:42-49.
10. de Haan L, Lavalaye J, van Bruggen M, et al. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry 2004;49:290-296.
11. de Haan L, Booij J, Lavalaye J, van Amelsvoort T, Linszen D. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology (Berl) 2006;183:500-505.
12. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518.
13. Meyer JS, Quenzer LF. Psychopharmacology: drugs, the brain, and behavior. Massachusettes: Sinauer; 2005.
14. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004;9:557-569.
15. Satel SL, Swann AC. Extrapyramidal symptoms and cocaine abuse. Am J Psychiatry 1993;150:347.
16. Bauer LO. Motoric signs of CNS dysfunction associated with alcohol and cocaine withdrawal. Psychiatry Res 1993;47:69-77.
17. Bauer LO. Resting hand tremor in abstinent cocaine-dependent, alcohol-dependent, and polydrug-dependent patients. Alcohol Clin Exp Res 1996;20:1196-1201.
18. Garwood ER, Bekele W, McCulloch CE, Christine CW. Amphetamine exposure is elevated in Parkinson's disease. Neurotoxicology 2006;27:1003-1006.
19. van Harten PN, van Trier JC, Horwitz EH, Matroos GE, Hoek HW. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry 1998;59:128-130.
20. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005;80:33-43.
21. Potvin S, Pampoulova T, Mancini-Marie A, Lipp O, Bouchard R-H, Stip E. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006;77:796-798.
22. Maat A, Fouwels A, de Haan L. Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacol Bull 2008;41:5-10.
23. Wang GJ, Volkow ND, Franceschi D, et al. Regional brain metabolism during alcohol intoxication. Alcohol Clin Exp Res 2000;24:822-829.
24. Martinez D, Gil R, Slifstein M, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 2005;58:779-786.
25. Sullivan EV, Deshmukh A, De Rosa E, Rosenbloom MJ, Pfefferbaum A. Striatal and forebrain nuclei volumes: contribution to motor function and working memory deficits in alcoholism. Biol Psychiatry 2005;57:768-776.
26. Sullivan EV, Rose J, Pfefferbaum A. Physiological and focal cerebellar substrates of abnormal postural sway and tremor in alcoholic women. Biol Psychiatry 2010;67:44-51.
27. Duke PJ, Pantelis C, Barnes TR. South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 1994;164:630-636.
28. Bossong MG, van Berckel BN, Boellaard R, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009;34:759-766.
29. Zaretsky A, Rector NA, Seeman MV, Fornazzari X. Current cannabis use and tardive dyskinesia. Schizophr Res 1993;11:3-8.
30. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005;57:594-608.
31. Niehaus DJH, du Plessis SA, Koen L, et al. Predictors of Abnormal Involuntary Movement in an African Schizophrenia Population. J Neuropsychiatry Clin Neurosci 2008;20:317-326.
32. Potvin S, Blanchet P, Stip E. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: A metaanalysis. Schizoph Res 2009;113:181-188.
33. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
34. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992;6:201-208.
35. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res 1994;11:239-244.
36. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, et al. Comparison of four scales measuring depression in schizophrenic patients. Eur Psychiatry 2000;15:274-277.
37. Potvin S, Sepehry AA, Stip E. Meta-analysis of depressive symptoms in dual diagnosis schizophrenia. Aust NZ J Psychiatry 2007;41:792-799.
38. Robert S, Hamner MB, Durkalski VL, Brown MW, Ulmer HG. An open-label assessment of aripiprazole in the treatment of PTSD. Psychopharmacol Bull 2009;42:69-80.
39. Mauri MC, Volonteri LS, Fiorentini A, Pirola R, Bareggi SR. Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother 2007;8:2207-2213.
40. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-265.
41. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
42. Barnes TRE. The Barnes Akathisia Rating Scale-Revisited. J Psychopharmacol 2003;17:365-370.
43. Anouti A, Koller WC. Tremor disorders. Diagnosis and management. West J Med 1995;162:510-513.
44. Gallimberti L, Canton G, Gentile N, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 1989;2:787-789.
45. Pycha R, Miller C, Barnas C, et al. Intravenous flunitrazepam in the treatment of alcohol withdrawal delirium. Alcohol Clin Exp Res 1993;17:753-757.
46. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J Abnorm Psychol 2003;112:393-402.
47. Kouri EM, Pope HG Jr. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 2000;8:483-492.
48. Ziedonis DM, Smelson D, Rosenthal RN, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11:315-339.
49. Glenthøj BY, Hemmingsen R. Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:23-25.
50. Bailey LG, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull 1997;33:177-181.
51. Evans SM, Walsh SL, Levin FR, Foltin RW, Fischman MW, Bigelow GE. Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans. Drug Alcohol Depend 2001;64:271-283.
52. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-369.
53. Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 2004;67:157-166.
54. Smith MJ, Thirthalli J, Abdallah AB, Murray RM, Cottler LB. Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr Psychiatry 2009;50:245-250.
55. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622.
56. Yeh HS, Lee YC, Sun HJ, Wan SR. Six months follow-up of patients with methamphetamine psychosis. Zhonghua Yi Xue Za Zhi (Taipei) 2001;64:388-394.
57. Brady KT, Killeen T, Jarrell P. Depression in alcoholic schizophrenic patients. Am J Psychiatry 1993;150:1255-1256.
58. Potvin S, Stip E, Lipp O, et al. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia. Am J Drug Alcohol Abuse 2008;34:75-82.
59. Quello SB, Brady KT, Sonne SC. Mood disorders and substance use disorder: a complex comorbidity. Sci Pract Perspect 2005;3:13-21.